How pharmaceutical leaders are successfully embedding equitable access into strategy, structure, and scale across LMICs
Download our white paper to discover how to build future-ready access strategies in LMICs – and elevate your role in shaping the next era of pharma leadership and global health equity.
Why it matters
With 88% of the world’s population living in LMICs, these markets are central to pharma’s future. The industry is shifting from donor-led programs to sustainable access ecosystems where equity is integrated into strategy, R&D, and commercialization. Companies that act now will unlock growth, strengthen healthcare systems, and advance global health equity.
What you’ll learn
- How pharma and biotech firms are making access a core business priority
- The execution gap – and how leading players are closing it
- Six strategic levers for scalable access: from early integration to impact measurement
- Case studies and blueprints spanning NCDs, rare diseases, and more
